

1 **A customizable multiplex protein microarray for antibody testing and its application**
2 **for tick-borne and other infectious diseases.**

3 Hari Krishnan Krishnamurthy^{1*}, Vasanth Jayaraman¹, Karthik Krishna¹, Tianhao Wang¹,
4 Kang Bei¹, Chithra Suresh², Shiny Matilda², Alex J Rai³, Renata Welc-Falęciak⁴, Agnieszka
5 Pawełczyk⁵, Lucas S. Blanton⁶, Aleš Chrdle⁷, Andrea Fořtová⁸, Daniel Růžek⁹, Gheyath K.
6 Nasrallah¹⁰, Laith J. Abu-Raddadi¹⁰, Duaa W. Al-Sadeq¹⁰, Marah Abed Alhakim Abdallah¹⁰,
7 Daniele Lilleri¹¹, Chiara Fornara¹¹, Piera D'Angelo¹¹, Milena Furione¹¹, Maria Söderlund-
8 Venermo¹², Klaus Hedman¹², Dimosthenis Chochlakis¹³, Anna Psaroulaki¹³, Eirini
9 Makridaki¹³, Artemis Ntoula¹³, John J. Rajasekaran¹.

10

11 1 Vibrant Sciences LLC., San Carlos, CA, United States of America

12 2 Vibrant America LLC., San Carlos, CA, United States of America

13 3 Columbia University, Irving Medical Center, Dept. of Pathology & Cell Biology

14 4 Department of Parasitology, Faculty of Biology, University of Warsaw, Diagnostic
15 Laboratory of Parasitic Diseases and Zoonotic Infections, Biological and Chemical Research
16 Centre, Warsaw, Poland.

17 5 Department of Immunopathology of Infectious and Parasitic Diseases, Medical University
18 of Warsaw, 3C Pawińskiego Street, 02-106, Warsaw, Poland

19 6 Department of Internal Medicine, Division of Infectious Diseases, University of Texas
20 Medical Branch, Galveston, TX 77555, USA.

21 7 Department of Infectious Diseases, Hospital Ceske Budejovice, Ceske Budejovice, Czech
22 Republic; Royal Liverpool University Hospital, Prescott St, Liverpool L7 8XP, UK.

23 8 Veterinary Research Institute, Brno, Czech Republic; Faculty of Science, Masaryk
24 University, Brno, Czech Republic

25 9 Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske
26 Budejovice, Czech Republic; Veterinary Research Institute, Brno, Czech Republic, Faculty of
27 Science, Masaryk University, Brno, Czech Republic.

28 10 Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha
29 P.O. Box 2713, Qatar.

30 11 Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.

31 12 Virology, University of Helsinki, Haartmaninkatu 3, FI-00290, Helsinki, Finland.

32 13 Laboratory of Clinical Microbiology and Microbial Pathogenesis, School of Medicine,
33 University of Crete, PC 70013, Heraklion – Crete – Greece.

34

35 Corresponding Author: * hari@vibrantsci.com (HKK)

36 Vasanth Jayaraman: vasanth.jayaraman@vibrantsci.com

37 Karthik Krishna: karthik@vibrantsci.com

38 Tianhao Wang: tianhao.wang@vibrantsci.com

39 Kang Bei: kang@vibrantsci.com

40 Chithra Suresh: chithra.s@vitasoft-tech.com

41 Shiny Matilda: shiny.m@vitasoft-tech.com

42 Alex J Rai: ajr2170@cumc.columbia.edu

43 Renata Welc-Falęciak: rwelc@biol.uw.edu.pl

44 Agnieszka Pawełczyk: agnieszka.pawelczyk@wum.edu.pl

45 Lucas Blanton: lsblanto@utmb.edu

46 Aleš Chrdle: chrdle.ales@nemcb.cz

47 Andrea Fořtová: fořtova@vri.cz

48 Daniel Růžek: ružekd@paru.cas.cz

49 Gheyath K. Nasrallah: gheyath.nasarallah@qu.edu.qa

- 50 Laith J. Abu-Raddadi: lja2002@qatar-med.cornell.edu
- 51 Duaa W. Al-Sadeq: da1206066@student.qu.edu.qa
- 52 Marah Abed Alhakim Abdallah: marah.hakim3@gmail.com
- 53 Daniele Lilleri: d.lilleri@smatteo.pv.it
- 54 Chiara Fornara: c.fornara@smatteo.pv.it
- 55 Piera D'Angelo: p.dangelo@smatteo.pv.it
- 56 Milena Furione: m.furione@smatteo.pv.it
- 57 Maria Söderlund-Venermo: maria.soderlund-venermo@helsinki.fi
- 58 Klaus Hedman: klaus.hedman@helsinki.fi
- 59 Dimosthenis Chochlakis: surreydimos@hotmail.com
- 60 Anna Psaroulaki: psaroulaki@uoc.gr
- 61 Eirini Makridaki: rmakridaki@yahoo.gr
- 62 Artemis Ntoula: artemisntoula@gmail.com
- 63 John J. Rajasekaran: jjrajasekaran@vibrantsci.com

64

65

66

67

68

69

70

71

72

73

74

75 **Abstract**

76 Tick-borne infections are the most common vector-borne diseases in the USA. Ticks harbor
77 and spread several infections with Lyme disease being the most common tickborne infection
78 in the US and Europe. Lack of awareness about tick populations, specific diagnostic tests,
79 and overlapping symptoms of tick-borne infections can often lead to misdiagnosis affecting
80 treatment and the prevalence data reported especially for non-Lyme tick-borne infections.
81 The diagnostic tests currently available for tick-borne diseases are severely limited in their
82 ability to provide accurate results and cannot detect multiple pathogens in a single run. The
83 multiplex protein microarray developed at Vibrant was designed to detect multiple
84 serological antibodies thereby detecting exposure to multiple pathogens simultaneously. Our
85 microarray in its present form can accommodate 400 antigens and can multiplex across
86 antigen types, whole cell sonicates, recombinant proteins, and peptides. A designed array
87 containing multiple antigens of several microbes including *Borrelia burgdorferi*, the Lyme
88 disease spirochete, was manufactured and evaluated. The immunoglobulin M (IgM) and G
89 (IgG) responses against several tick-borne microbes and other infectious agents were
90 analyzed for analytical and clinical performance. The microarray improved IgM and IgG
91 sensitivities and specificities of individual microbes when compared with the respective gold
92 standards. The testing was also performed in a single run in comparison to multiple runs
93 needed for comparable testing standards. In summary, our study presents a flexible multiplex
94 microarray platform that can provide quick results with high sensitivity and specificity for
95 evaluating exposure to varied infectious agents especially tick-borne infections.

96 **Keywords:** Tick-borne infections, Lyme disease, multiplex, microarray, immunoglobulin,
97 tick bite, co-infections, infectious disease.

98

99

100 **Introduction**

101 Most vector-borne infections in the USA can be attributed to pathogens transmitted via tick
102 bites. Of all tick-borne infections identified to date, Lyme disease is the most prevalent
103 infection [1]. Lyme disease is a potentially serious bacterial infection transmitted by ticks and
104 was first reported in the mid-1970s in the USA. The etiological agent was identified later as
105 *Borrelia burgdorferi* [2,3,4]. Several studies have reported the presence of co-infections
106 along with Lyme disease [5] including *Babesia spp.* [6], *Bartonella spp.* [7], *Ehrlichia spp.*
107 [8], *Anaplasma phagocytophilum* [8], Powassan Virus [9], *Toxoplasma gondii* [10],
108 *Rickettsia spp.* [11], tick-borne encephalitis virus [12], and West Nile virus [13].
109 Additionally, prolonged exposure to Lyme and other tick-borne infections could potentially
110 weaken the patient's immune system increasing the risk of infections like Epstein Barr virus
111 [14], cytomegalovirus [14], parvovirus B19 [5], coxsackie virus [15], HSV-1 [16], HSV-2
112 [16], and HHV-6 [14].

113

114 Ticks have been shown to transmit more than one infectious agent in a single bite. For
115 instance, a study by Wormser et al. showed that there was a chance of getting infected with *A.*
116 *phagocytophilum* (30%) and *B. microti* (24%) along with Lyme disease [17]. Currently,
117 multi-tiered testing is carried out for diagnosing tick-borne infections [18]
118 (<https://tinyurl.com/yeyxevve>). In this method, the infectious agents are tested sequentially,
119 starting with Lyme disease. This method is time-consuming and can often lead to delayed
120 diagnosis, accompanied with high cost to the patient [18, 19] (<https://tinyurl.com/yeyxevve>).
121 Testing for multiple infections in a single run can help physicians arrive at an accurate
122 diagnosis especially since Lyme disease shares symptoms with other vector-borne co-
123 infections [20]. The existing diagnostic assays possess various limitations that restrict their
124 applicability in the diagnosis of these infections. The diagnosis of Lyme disease and other

125 infections using several blot-based and single-plex ELISA tests remain rudimentary in terms
126 of arriving at a diagnostic conclusion [21]. Additionally, blot-based assays may have
127 overlapping proteins with similar mass requiring additional testing to tease out the specific
128 antigen to which the antibody is bound. A multiplex system can detect the biomarkers of
129 Lyme disease, potential co-infections, and other infections in a single run. A serology-based
130 multiplexing system may be preferred to a PCR multiplex system mainly due to its
131 accessibility, for instance using dried blood spots [22]. Additionally, serology overcomes the
132 issue of low availability of genetic material due to the transient nature of some of these
133 organisms [23]. A serological-based system is also ideal for population screening and
134 surveillance since it can indicate past exposure to a pathogen.

135

136 Our customisable protein microarray design includes antigens physically separated by design
137 unlike blot assays and can multiplex across species. Multiplexing can also be done across
138 antigen types such as recombinant proteins, peptides, and lysates simultaneously. This
139 method can lower test costs since all the manufacturing is automated using bio customised
140 semiconductor processes similar to how electronic chips are made. The multiplex microarray
141 has three main advantages over the existing technologies. It has an ultra-high-density array
142 surface with high reproducibility and better throughput. It can detect a large number of
143 antibodies against varied infectious agents at the same time. Detection of antibodies can be
144 performed using low sample volumes with low cost and a fast turnaround time [21]. Given
145 the flexible nature of the multiplex platform, we aimed to provide a multiplexed testing
146 solution for Lyme, its co-infections, and other possible infections of interest.

147

148 **Materials and Methods**

149 **Patients Sera**

150 The sera from 2990 individuals were collected after seeking appropriate Institutional Review
151 Board (IRB) approval under respective collaborators (Supplementary Table 6). Table 1 lists
152 the provided samples for Lyme disease, co-infections, and other infections along with the
153 counts, respective collaborators and methods used to ascertain the clinical diagnosis by the
154 physician. These reference sera were tested at Vibrant America Clinical Labs (CLIA and
155 CAP accredited facility) by laboratory personnel in a blinded manner. The sera from healthy
156 patients were considered negative and were used to set the cut-off values and were
157 investigated under IRB exemption (work order #1-1574995-1) determined by the Western
158 Institutional Review Board (WIRB) to employ de-linked and de-identified human specimens
159 and medical data for research findings. The negative sera were collected from across the US
160 including endemic and nonendemic regions for these infections.

161

162 **Processing of Wafers**

163 Wafers were functionalized as described previously [21,24] (<https://tinyurl.com/mr9ctppy>).
164 Briefly, silicon wafers were exposed to an environment of pure oxygen for 2h followed by
165 washing (deionized Water) and coating (1% (vol/vol) with 3-aminopropyltriethoxysilane
166 (APTES) in N-methylpyrrolidone (NMP). Curing was carried out at 120 °C for 60 minutes
167 under an N₂ atmosphere and humidity-controlled environment. Coating and incubation of the
168 wafer with a co-polymer solution of poly (L-lysine) and poly (lactic acid) for 24h were
169 carried out to increase the binding efficiency of the surface on to which the antigens were
170 immobilized via passive adsorption/hydrophobic interactions with the copolymers [Figure
171 1].

172

173 **Immobilization of Antigens**

174 The antigens included in the assay are listed in Table 2. Pathogens transmitted by ticks and
175 their respective antigens for potential future additions are listed in Figure 2 [25-30]
176 (<https://tinyurl.com/37dprsy7>). The recombinant antigens were expressed in *E. coli* bacteria
177 using full-length cDNA coding for the respective antigens fused with a hexa histidine
178 purification tag. The whole cell sonicate was obtained from organisms cultured according to
179 ATCC protocols prior to lysing them which yielded a cocktail of the cell membrane, cell
180 wall, and cytosolic proteins. Peptide antigens were synthesized by photolithography as shown
181 in our previous publications [31,32]. The capture antigens including the recombinant antigens
182 that mimic the natural pathogen and the whole-cell sonicate were incubated on the wafer at a
183 concentration of 1.0 µg/ml and reacted for 24h at 4 °C. The unbound antigens were removed
184 by washing with aqueous phosphate buffer and the unreacted substrate was quenched with a
185 blocking solution containing BSA and glycine. The immobilized antigens were classified
186 with unique identifiers assigned to each wafer. In this study, we employed the microarray to
187 detect Lyme disease, co-infections, and other agents of interest including, *B. microti*, *B.*
188 *henselae*, *A. phagocytophilum*, *E. chaffeensis*, *R. typhi*, Powassan virus , tick-borne
189 encephalitis virus, West Nile virus, coxsackie virus, cytomegalovirus, Epstein Barr virus,
190 parvovirus B19, *T. gondii*, HSV-1, HSV-2, and HHV-6 [Figure 2].

191

192 **Pillar Plate Assembly**

193 Individual wafers were stealth diced into 0.70 x 0.70mm² microchips for each antigen. A
194 standard die-sorting system was used to pick and place these wafers onto individual carrier
195 tapes. The carrier tapes were then placed onto a high-throughput surface mount technology
196 (SMT) component placement system. Finally, microchips were mounted onto 24 pillar plates
197 and each pillar contains 87 microchips with each chip designated for one antigen –
198 recombinant protein, peptide or whole cell sonicates [Figure 1].

199

200 **Immunochip assay and Antibody detection**

201 Serum samples were probed using 1:20 dilution on the pillar plate and incubated for 1h at
202 room temperature followed by alternate washing and incubation as described previously [21].
203 The plate was then incubated for an hour with the secondary antibody (1:2000 dilution of
204 Goat Anti-Human IgG HRP and Goat Anti-Human IgM HRP individually) and washed with
205 TBST buffer followed by DI Water. The plates were left for drying preceding the addition of
206 chemiluminescent substrate and the performance of chemiluminescent imaging. An enhanced
207 IgM sensitivity was achieved by pre-reacting the sera with proprietary assay components
208 leading to IgG stripping prior to IgM testing.

209

210 The detection of multiplex antibodies is based on the chemiluminescent immunoassay and
211 can be performed using <200 μ L of serum. Sample dilution, multi-step incubation, and multi-
212 solution washing are programmed into liquid handlers. The immunochip has the capacity to
213 assay 192 individual specimens in 2h. Raw chemiluminescent signals for each probe are
214 extracted and converted into intensity plots by an in-house reporter software. This method of
215 automatic antigen detection can dramatically shorten the turnaround time, reduce the cost of
216 labor and instrument, and eliminate the need for manual handling and subjective
217 interpretation of the WB or IB test results when compared to the traditional two-tiered testing
218 recommended by the CDC. All the antibodies are detected in a single run.

219

220 **Data analysis**

221 An in-house software extracts the chemiluminescent signals from the generated images which
222 were converted to intensity plots. The average intensity of each antibody was compared with
223 the cut-off values assigned for each antigen to track seropositivity.

224

225 **Results**

226 **Custom Protein Microarray Platform**

227 The main components of the ImmunoChip platform include multiple silicon-based $0.70 \times$
228 0.70 mm^2 microchips that are laser diced from antigen-immobilized wafers, a customized 24
229 well compatible plate containing 24 pillars, each containing 87 microchips that are picked
230 and placed into a multiplex microarray assembly, and a high-resolution imager capable of
231 simultaneously detecting chemiluminescent signals from labelled antigen–antibody reactions
232 at each microchip throughout the multiplex microarray (Figure 1). Each chip can be
233 considered analogous to an individual band in a Western blot; however, the proteins are
234 physically separated eliminating cross-reactive issues usually seen in blot-based assays for
235 proteins with similar mass. Figure 1 provides an overview of the microarray manufacturing
236 process. Figure 2 shows the individual chips that are placed in each pillar, a single serum
237 sample will be applied to each pillar thereby assaying the antibodies in serum against all
238 antigens at the same time.

239

240 **Analysis of serological response**

241 The Vibrant tick-borne disease panel tests for IgG and IgM antibodies for Lyme disease and
242 other infectious agents as mentioned in Table 2 and Figure 2. The IgM and IgG immune
243 responses were analysed, and the clinical sensitivities and specificities were tabulated in
244 Table 3. The samples reacted with a specific immunoreactive epitope of the 87 different
245 antigens that were being tested. The immunoreactivity of these antigens was contrasted with
246 that of the controls.

247

248 **Enhanced IgM Assay**

249 IgM antibodies are the primary antibodies produced by the immune system during infections,
250 but they make up only 5% to 10% of all the circulating antibodies [33]. An in-house IgM
251 assay was developed to remove most IgG antibodies and other non-specific proteins from the
252 serum prior to the IgM immunoassay. This helped to increase the sensitivity and specificity
253 of the assay. Human IgG was removed by incubating the serum with a purified goat anti-
254 human (GAH) IgG Fc fragment and proprietary assay reagents.

255

256 **Analytical Performance**

257 The analytical performance of the immunochip was evaluated for precision
258 (repeatability/reproducibility), analytical sensitivity, reportable range, linearity, and matrix
259 equivalency studies. Samples for negatives, low or moderate positives, and high positives
260 were run with duplication to determine the analytical performance metrics. The precision
261 study used a panel of 11 samples and was run over a period of 20 days with 2 duplicates per
262 run and 4 runs per day. The results are tabulated as shown in Supplementary Table 1. Lot to
263 Lot reproducibility was also tested to check for variation in the manufacturing of the pillar
264 plates by running a panel of 11 samples with 5 replicates per run, 3 runs per day over a period
265 of 5 days using 3 manufactured lots. The results are tabulated as shown in Supplementary
266 Table 2. Testing of protein-free serum matrix samples and low antibody concentration
267 samples with 2 replicates per run, 2 runs per day over a period of three days was used to
268 determine analytical sensitivity. The limit of blank (LoB) and limit of quantitation (LoQ) was
269 calculated using the mean and standard deviation of the blank and the low antibody
270 concentration samples as shown in Supplementary Table 3. The linearity and reportable range
271 were verified by running samples with varying levels of antibodies and checking assay

272 recovery, the results are tabulated in Supplementary Table 4. Matrix equivalence studies are
273 shown in Supplementary Table 5. The potential interference of specific endogenous and
274 exogenous substances with the immunochip was evaluated by performing an interfering
275 substance study. The interfering substances tested were 60 mg/dl bilirubin, 100 mg/ml
276 cholesterol, 1000 mg/ml triglycerides, 1000 mg/ml hemoglobin, and 6 g/dl albumin. There
277 was no interference between the immunochip and the substances tested at the mentioned
278 levels.

279

280 **Clinical Sensitivity and Specificity**

281 Table 3 provides an overview of the IgG and IgM sensitivities measured by the Vibrant
282 microarray. This is compared with the sensitivities and specificities of the current gold
283 standard tests for the particular pathogen. The Vibrant microarray was able to achieve high
284 sensitivities and specificities when compared with the gold standards for each
285 pathogen. Supplementary Table 7 provides more details on the gold standard diagnostic tests
286 for the pathogens along with the modes of transmission and their endemic regions.

287

288 **Evaluating the antigens of *Borrelia burgdorferi***

289 In this study, individual antigens of *B. burgdorferi* were tested for reactivity with IgG and
290 IgM antibodies (Table 4). The heat map (Figure 3) shows the performance metrics of the
291 different antigens. Testing for Lyme disease since 1994 has been based on conventional two-
292 tiered testing (CTTT) where an enzyme immunoassay (EIA) is followed by a specific
293 immunoblot for a definitive diagnosis. Recently, CTTT has been replaced with a modified
294 two-tier testing (MTTT) in which an EIA using whole cell sonicate is followed by an EIA
295 using C6 peptide. This shows the increasing shift away from blot-based testing to
296 conventional ELISA. MTTT removes the burden of immunoblots which are tedious to run,

297 more expensive and could have subjective interpretation of bands [49]. Complete
298 replacement of immunoblots can be done using a microarray platform such as the one
299 described here. The full data set would be available to the physicians to make a nuanced
300 diagnosis instead of a narrow subset of antigens run on ELISAs.

301

302 **Discussion**

303 Ticks are among the most important sources of vector-borne infections in the US [50]. The
304 spread of ticks across the US has been steadily increasing over the past decades. In parallel,
305 the discovery of novel pathogens that are spread by ticks has also seen dramatic increases
306 [51]. Currently, there are 11 major tickborne diseases according to the CDC namely, Lyme
307 disease, babesiosis, ehrlichiosis, Rocky Mountain spotted fever, Southern tick-associated rash
308 illness, tick-borne relapsing fever, tularemia, anaplasmosis, Colorado tick fever, and
309 Powassan encephalitis [52] (<https://www.cdc.gov/ticks/diseases/index.html>). Patients are
310 rarely tested for all possible infections that could be transmitted via a tick bite [53]. The
311 current diagnostic tests are severely limited in distinguishing various tick-borne infections
312 and several studies have revealed that non-Lyme tick-borne infections are heavily
313 underdiagnosed [54].

314

315 Among varied testing options PCR and serology-based assays are reliable and most widely
316 used. PCR has several advantages as it detects pathogenic DNA/RNA which conclusively
317 proves the organism's presence. It has high specificity and has a high throughput with assay
318 run times of about 2 hours. It can also detect the infection during its early stages [55]. There
319 are however certain drawbacks to testing using PCR, especially with tickborne infections.
320 Pathogens transmitted by ticks may be transient in the blood resulting in false negative PCR

321 results in tick-borne diseases, namely, *B. burgdorferi*, *R. typhi*, *T. gondii*, HSV-1, EBV,
322 TBEV, and WNV [23]. PCR testing requires specialised laboratories and equipment for
323 testing. PCR may not detect all strains and variants and is limited to detecting known
324 pathogens [56]. Multiplexing using PCR is limited due to fixed number of analytes that can
325 be parallelly read using PCR instrumentation.

326

327 Serology-based testing has several advantages when it comes to tick-borne infection testing.
328 It has the ability to comprehensively assess immune responses and simultaneously detect
329 exposure to multiple pathogens including previous and unresolved infections. Testing two
330 times with a time interval in between can also help diagnose active infections based on
331 altered serum antibody profiles. Simultaneous detection of antibodies against multiple tick-
332 borne pathogens using a single sample and providing a comprehensive view of the patient's
333 immune response is a key advantage of serology-based multiplex testing [23]. The testing can
334 also be done in resource poor settings with collection using a dried blood spot [22].
335 Serological testing can diagnose tick-borne diseases even in the later stages when pathogen
336 detection through molecular methods becomes more challenging [23,57]. It also reduces the
337 risk of false negatives [57]. Serological multiplex testing being cost-effective can also
338 contribute to surveillance and epidemiological studies by providing valuable data on the
339 prevalence and distribution of tick-borne diseases, enhancing our understanding of disease
340 dynamics [58]. However, serological studies have their own limitations. Serological testing
341 may not be able to detect early/recent infections. It relies heavily on the timing of sample
342 collection and the host's immune responses. In certain cases, molecular testing may be needed
343 to confirm serological testing [23]. Despite all this, the benefits of serology testing outweigh
344 its limitations which is why it is recommended by the CDC as the standard of testing for
345 Lyme disease.

346

347 Apart from PCR and ELISA serology tests, IFA and culture methods have also been
348 suggested for diagnosing tick-borne infections. Testing using IFA is limited due to a lack of
349 standardized antigenic targets, the subjective establishment of positive thresholds, and cross
350 reactivity. These factors can result in varying accuracy of IFA results across laboratories [23].
351 Furthermore, Bacterial or viral cultures are not recommended for the diagnosis of tick-borne
352 infections. This is due to the time-consuming nature of the test, the need for special media,
353 and procedures that are only performed at specific laboratories [61].

354

355 This study employed a serology-based microarray developed at Vibrant to multiplex Lyme
356 and other tick-borne infections along with a few other infections of interest. The uniqueness
357 of the microarray lies in the application of the immunodominant antigens that eliminate
358 nonspecific binding with high sensitivity needed for accurate diagnosis. Antigens could be
359 evaluated in a multiplex setting to gauge their performance with clinical samples to pick the
360 ideal set of antigens for any infection. To the best of our knowledge, this is the first report on
361 the broad panel of antigens for Lyme disease and its co-infection testing in such a flexible
362 format. The structure of the Vibrant pillar plate is designed to encompass 400 probe chips at
363 each pillar facilitating the detection of an array of co-infections in a single run, saving cost,
364 labor, and time. Further compaction of the chip allows improved performance by enhancing
365 multiplexing and widening its clinical applications. The microarray platform is advantageous
366 over other existing gold standards for tick-borne diseases and was able to overcome several
367 of their limitations. Average time for multitier testing for several tickborne pathogens could
368 take several months whereas the microarray technology takes only about a day to perform
369 [21]. The microarray detected 17 tick-borne and other infections along with Lyme disease
370 with sensitivities and specificities listed in Table 3.

371

372 In conclusion, the protein microarray with a multiplex of antigens was validated for Lyme
373 and its co-infections. The impact of simultaneous testing of co-infections leads to focused and
374 efficacious therapeutic recommendations. This approach caters to the diagnostic needs of
375 patients owing to its high sensitivity and specificity, affordable cost, quick availability of
376 results, and low sample volume requirement. Measures for syndromic surveillance,
377 diagnostic preparedness in disease outbreak investigations, personal protection, and education
378 of clinical health professionals and patients could pave the way for controlling tick-borne
379 infections better. As the known repertoire of antigens increases, this flexible microarray
380 format can be customised to include these new antigens. Future editions could also include
381 other infections/agents namely Colorado tick fever, heartland virus, rickettsiosis, Rocky
382 Mountain spotted fever, Southern tick-associated rash illness, tick-borne relapsing fever, and
383 tularemia which can be tested in parallel. Novel antigens for pathogens which may include
384 whole cell sonicates, recombinant proteins or peptide epitopes can be added as the science
385 progresses leading to continuous improvement in diagnostic technology for detecting tick-
386 borne infections.

387

388 Declarations:

389 Author Contributions

390 Conception and study design: HKK, JJR, VJ. Performing experiments: KK, TW. Analysis
391 and interpretation: KB, KK. Writing-original draft: HKK, CS, SM. Review and editing:
392 HKK, CS, AJR, RWF, AP, LSB, AC, AF, DR, GKN, LJA, DWA, MAA, DL, CF, PD, MF,
393 MSV, KH, DC, AP, EM, and AN. Sample resources: RWF, AP, LSB, AC, AF, DR, GKN,
394 LJA, DWA, MAA, DL, CF, PD, MF, MSV, KH, DC, AP, EM, and AN. All authors
395 reviewed and approved the final manuscript.

396 Competing interests

397 The authors have read the journal's policy and the authors of this manuscript have the
398 following competing interests: CS and SM are paid employees of Vibrant America LLC. KK,
399 VJ, TW, KB, HKK, and JJR are paid employees of Vibrant Sciences LLC. The other authors
400 are academic collaborators who provided samples and assisted in the review and editing of
401 the manuscript. AJR is a paid consultant of Vibrant America LLC. Vibrant America offers
402 commercial testing for Lyme disease and other infectious diseases and could benefit from
403 increased testing.

404 Funding

405 Vibrant America provided funding for this study in the form of salaries for authors [CS, SM,
406 KK, VJ, TW, KB, HKK, JJR]. The funders had no role in study design, data collection,
407 analysis, decision to publish, or preparation of the manuscript.

408 Acknowledgment

409 Vibrant Sciences LLC developed the microarray technology showcased in the publication.
410 All IP associated with the microarray manufacture and diagnostics belongs to Vibrant
411 Sciences. The specific roles of authors are stated in the author contribution section.

412 Availability of Data

413 The data used to support the findings of this study can be acquired from Vibrant America
414 LLC.

415 References

416 1. Rochlin, I., & Toledo, A. (2020). Emerging tick-borne pathogens of public health
417 importance: a mini-review. *J Med Microbiol*, 69(6), 781–791.

- 418 2. Burgdorfer, W., Barbour, A. G., Hayes, S. F., Benach, J. L., Grunwaldt, E., & Davis,
419 J. P. (1982). Lyme disease—a tick-borne spirochetosis?. *Science*, 216(4552), 1317-
420 1319.
- 421 3. Johnson, R. C., Schmid, G. P., Hyde, F. W., Steigerwalt, A. G., & Brenner, D. J.
422 (1984). *Borrelia burgdorferi* sp. nov.: etiologic agent of Lyme disease. *International*
423 *Journal of Systematic and Evolutionary Microbiology*, 34(4), 496-497.
- 424 4. Steere, A. C., Strle, F., Wormser, G. P., Hu, L. T., Branda, J. A., Hovius, J. W., ... &
425 Mead, P. S. (2016). Lyme borreliosis. *Nature reviews Disease primers*, 2(1), 1-19.
- 426 5. Berghoff, W. (2012). Chronic Lyme Disease and Co-infections: Differential
427 Diagnosis. *Open Neurol J*, 6(Suppl 1), 158–178.
- 428 6. Knapp, K. L., & Rice, N. A. (2015). Human Coinfection with *Borrelia burgdorferi*
429 and *Babesia microti* in the United States. *J Parasitol Res*, 16(3), 385–391.
- 430 7. Angelakis, E., Billeter, S. A., Breitschwerdt, E. B., Chomel, B. B., & Raoult, D.
431 (2010). Potential for Tick-borne Bartonellosis. *Emerg Infect Dis*, 16(3), 385–391.
- 432 8. Ismail, N., Bloch, K. C., & McBride, J. W. (2010). Human Ehrlichiosis and
433 Anaplasmosis. *Clin Lab Med*, 30(1), 261–292.
- 434 9. Hart, C. E., Middleton, F. A., & Thangamani, S. (2022). Infection with *Borrelia*
435 *burgdorferi* Increases the Replication and Dissemination of Coinfecting Powassan
436 Virus in *Ixodes scapularis* Ticks. *Viruses*, 14(7), 1584.
- 437 10. Ben-Harari, R. R. (2019). Tick transmission of toxoplasmosis. *Expert Review of Anti-*
438 *infective Therapy*, 17(11), 911-917.
- 439 11. Koetsveld, J., Tijssen-Klasen, E., Herremans, T., Hovius, J. W. R., & Sprong, H.
440 (2016). Serological and molecular evidence for spotted fever group *Rickettsia* and
441 *Borrelia burgdorferi* sensu lato co-infections in The Netherlands. *Ticks Tick Borne*
442 *Dis*, 7(2), 371-7.
- 443 12. Gustafson, R., Svenungsson, B., Gardulf, A., Stiernstedt, G., & Forsgren, M. (1990).
444 Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish
445 population. *Scand J Infect Dis*, 22(3), 297-306.
- 446 13. Lawrie, C. H., Uzcátegui, N. Y., Gould, E. A., & Nuttall, P. A. (2004). Ixodid and
447 argasid tick species and West Nile virus.
- 448 14. Smith, A., Oertle, J., Warren, D., & Prato, D. (2015). Chronic Lyme Disease Complex
449 and Its Commonly Undiagnosed Primary and Secondary Co-Infections. *Open Journal*
450 *of Medical Microbiology*, 5(3).
- 451 15. Freundt, E. C., Beatty, D. C., Stegall-Faulk, T., & Wright, S. M. (2005). Possible
452 Tick-Borne Human Enterovirus Resulting in Aseptic Meningitis. *J Clin Microbiol*,
453 43(7), 3471–3473.
- 454 16. Gylfe, A., Wahlgren, M., Fahlén, L., & Bergström, S. (2002). Activation of latent
455 Lyme borreliosis concurrent with a herpes simplex virus type 1 infection. *Scand J*
456 *Infect Dis*, 34(12), 922-4.
- 457 17. Wormser, G. P., McKenna, D., Scavarda, C., Cooper, D., El Khoury, M. Y.,
458 Nowakowski, J., ... & Wong, S. J. (2019). Co-infections in persons with early Lyme
459 disease, New York, USA. *Emerging infectious diseases*, 25(4), 748.
- 460 18. Quest diagnostics. (2018). *Tick-borne Diseases*. Quest Diagnostics.
- 461 19. Drew, D., & Hewitt, H. (2006). A qualitative approach to understanding patients'
462 diagnosis of Lyme disease. *Public Health Nursing*, 23(1), 20-26.

- 463 20. Beck, S., Nakajima, R., Jasinskas, A., Abram, T. J., Kim, S. J., Bigdeli, N., ... &
464 Zhao, W. (2022). A protein microarray-based respiratory viral antigen testing
465 platform for COVID-19 surveillance. *Biomedicines*, *10*(9), 2238.
- 466 21. Jayaraman, V., Krishna, K., Yang, Y., Rajasekaran, K. J., Ou, Y., Wang, T., Bei, K.,
467 Krishnamurthy, H. K., Rajasekaran, J. J., Rai, A. J., & Green, D. A. (2020). An ultra-
468 high-density protein microarray for high throughput single-tier serological detection
469 of Lyme disease. *Scientific Reports*, *10*, 18085.
- 470 22. Grossberg, A. N., Koza, L. A., Ledreux, A., Prusmack, C., Krishnamurthy, H. K.,
471 Jayaraman, V., Granholm, A. C., & Linseman, D. A. (2021). A multiplex
472 chemiluminescent immunoassay for serological profiling of COVID-19-positive
473 symptomatic and asymptomatic patients. *Nature communications*, *12*(740).
- 474 23. Tokarz, R., Mishra, N., Tagliaferro, T., Sameroff, S., Caciula, A., Chauhan, L., Patel,
475 J., Sullivan, E., Gucwa, A., Fallon, B., Golightly, M., Molins, C., Schriefer, M.,
476 Marques, A., Briese, T., & Lipkin, W. I. (2018). A multiplex serologic platform for
477 diagnosis of tick-borne diseases. *Sci Rep*, *8*(3158).
- 478 24. Rajasekaran, J. J., Jayaraman, V., Wang, T., Bei, K., Krishnamurthy, H. K. (2016).
479 Methods, systems, and arrays for biomolecular analysis. *Patent No. 9417236B2*.
480 United States.
- 481 25. Centers for Disease Control and Prevention. (2022, August 5). *Tickborne Diseases of*
482 *the United States*. Centers for Disease Control and Prevention. Retrieved September
483 8, 2023.
- 484 26. Alhassan, A., Liu, H., McGill, J., Cerezo, A., Jakkula, L. U. M. R., Nair, A. D. S.,
485 Winkley, E., Olson, S., Marlow, D., Sahni, A., Narra, H. P., Sahni, S., Henningson, J.,
486 & Ganta, R. R. (2019). Rickettsia rickettsii Whole-Cell Antigens Offer Protection
487 against Rocky Mountain Spotted Fever in the Canine Host. *Infection and immunity*,
488 *87*(2), e00628-18.
- 489 27. Blanc, G., Ngwamidiba, M., Ogata, H., Fournier, P. E., Claverie, J. M., & Raoult, D.
490 (2005). Molecular evolution of rickettsia surface antigens: evidence of positive
491 selection. *Molecular biology and evolution*, *22*(10), 2073-2083.
- 492 28. Pornwiroon, W., Bourchookarn, A., Paddock, C. D., & Macaluso, K. R. (2009).
493 Proteomic analysis of Rickettsia parkeri strain portsmouth. *Infection and immunity*,
494 *77*(12), 5262–5271.
- 495 29. Kubelkova, K., & Macela, A. (2021). *Francisella* and Antibodies. *Microorganisms*,
496 *9*(10), 2136.
- 497 30. Zhu, Y., Wu, Y., Chai, Y., Qi, J., Peng, R., Feng, W. H., & Gao, G. F. (2017). The
498 Postfusion Structure of the Heartland Virus Gc Glycoprotein Supports Taxonomic
499 Separation of the Bunyaviral Families Phenuiviridae and Hantaviridae. *Journal of*
500 *virology*, *92*(1), e01558-17.
- 501 31. Marietta, E. V., Choung, R. S., Van Dyke, C. T., Brantner, T. L., Rajasekaran, J. J.,
502 Pasricha, P. J., Wang, T., Bei, K., Krishna, K., Krishnamurthy, H. K., Snyder, M. R.,
503 Jayaraman, V., & Murray, J. A. (2016). Determination of B-Cell Epitopes in Patients
504 with Celiac Disease: Peptide Microarrays. *PLoS One*, *11*(1), e0147777.
- 505 32. Rostamkolaei, S. K., Choung, R. S., Ju, J. M., Marietta, E. V., Van Dyke, C. T.,
506 Rajasekaran, J. J., Jayaraman, V., Wang, T., Bei, K., Rajasekaran, K. E., Krishna, K.,
507 Krishnamurthy, H. K., & Murray, J. A. (2019). Synthetic Neopeptides of the

- 508 Transglutaminase-Deamidated Gliadin Complex as Biomarkers for Diagnosing and
509 Monitoring Celiac Disease. *Gastroenterology*, 156(3), 582-591.e1.
- 510 33. Terry, W. D., & Fahey, J. L. (1964). SUBCLASSES OF HUMAN GAMMA-2-
511 GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE
512 CHAINS. *Science*, 146(3642), 400-1.
- 513 34. Moore, A., Nelson, C., Molins, C., Mead, P., & Schriefer, M. (2016). Current
514 guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of
515 Lyme disease, United States. *Emerging infectious diseases*, 22(7), 1169.
- 516 35. Ortiz, J. F., Millhouse, P. W., Cox, Á. M., Campoverde, L., Kaur, A., Wirth, M., &
517 Atoot, A. (2020). Babesiosis: appreciating the pathophysiology and diverse sequela of
518 the infection. *Cureus*, 12(10).
- 519 36. Allizond, V., Costa, C., Sidoti, F., Scutera, S., Bianco, G., Sparti, R., ... & Musso, T.
520 (2019). Serological and molecular detection of Bartonella henselae in specimens from
521 patients with suspected cat scratch disease in Italy: A comparative study. *PloS one*,
522 14(2), e0211945.
- 523 37. Reller, M. E., & Dumler, J. S. (2018). Development and clinical validation of a
524 multiplex real-time quantitative PCR assay for human infection by Anaplasma
525 phagocytophilum and Ehrlichia chaffeensis. *Tropical medicine and infectious disease*,
526 3(1), 14.
- 527 38. Stewart, A. G., & Stewart, A. G. (2021). An update on the laboratory diagnosis of
528 Rickettsia spp. infection. *Pathogens*, 10(10), 1319.
- 529 39. Thomm, A. M., Schotthoefer, A. M., Dupuis, A. P., Kramer, L. D., Frost, H. M.,
530 Fritsche, T. R., ... & Kehl, S. C. (2018). Development and validation of a serologic
531 test panel for detection of Powassan virus infection in US patients residing in regions
532 where Lyme disease is endemic. *Msphere*, 3(1), e00467-17.
- 533 40. Reusken, C., Boonstra, M., Rugebregt, S., Scherbeijn, S., Chandler, F., Avšič-Županc,
534 T., ... & GeurtsvanKessel, C. H. (2019). An evaluation of serological methods to
535 diagnose tick-borne encephalitis from serum and cerebrospinal fluid. *Journal of*
536 *Clinical Virology*, 120, 78-83.
- 537 41. Sambri, V., Capobianchi, M. R., Cavrini, F., Charrel, R., Donoso-Mantke, O.,
538 Escadafal, C., ... & Zeller, H. (2013). Diagnosis of west nile virus human infections:
539 overview and proposal of diagnostic protocols considering the results of external
540 quality assessment studies. *Viruses*, 5(10), 2329-2348.
- 541 42. Bryant, P. A., Tingay, D., Dargaville, P. A., Starr, M., & Curtis, N. (2004). Neonatal
542 coxsackie B virus infection—a treatable disease?. *European journal of pediatrics*,
543 163, 223-228.
- 544 43. A Ross, S., Novak, Z., Pati, S., & B Boppana, S. (2011). Overview of the diagnosis of
545 cytomegalovirus infection. *Infectious Disorders-Drug Targets (Formerly Current*
546 *Drug Targets-Infectious Disorders)*, 11(5), 466-474.
- 547 44. Jensen, H. B. (2004). Virologic diagnosis, viral monitoring, and treatment of Epstein-
548 Barr virus infectious mononucleosis. *Current Infectious Disease Reports*, 6, 200-207.
- 549 45. Manaresi, E., Gallinella, G., Zuffi, E., Bonvicini, F., Zerbini, M., & Musiani, M.
550 (2002). Diagnosis and quantitative evaluation of parvovirus B19 infections by
551 real-time PCR in the clinical laboratory. *Journal of medical virology*, 67(2), 275-
552 281.

- 553 46. Souza, I. M. F. N. B. D., Siqueira, V. D. S., Ribeiro, I. D. C., Moraes, L. S. P., Prado,
554 D. P. G. D., Rezende, S. R., ... & Rezende, H. H. A. (2023). Molecular and
555 serological diagnosis of toxoplasmosis: a systematic review and meta-analysis.
556 *Revista do Instituto de Medicina Tropical de São Paulo*, 65, e19.
- 557 47. Singh, A., Preiksaitis, J., & Romanowski, B. (2005). The laboratory diagnosis of
558 herpes simplex virus infections. *Canadian Journal of Infectious Diseases and Medical
559 Microbiology*, 16(2), 92-98.
- 560 48. Norton, R. A., Caserta, M. T., Hall, C. B., Schnabel, K., Hocknell, P., & Dewhurst, S.
561 (1999). Detection of human herpesvirus 6 by reverse transcription-PCR. *Journal of
562 clinical microbiology*, 37(11), 3672-3675.
- 563 49. Lipsett, S. C., Branda, J. A., & Nigrovica, L. E. (2019). Evaluation of the Modified
564 Two-Tiered Testing Method for Diagnosis of Lyme Disease in Children. *J Clin
565 Microbiol*, 57(10), e00547-19.
- 566 50. Eisen, R. J., Kugeler, K. J., Eisen, L., Beard, C. B., & Paddock, C. D. (2017). Tick-
567 Borne Zoonoses in the United States: Persistent and Emerging Threats to Human
568 Health. *ILAR J*, 58(3), 319-335.
- 569 51. Paddock CD, Lane RS, Staples JE, et al. (2016). CHANGING PARADIGMS FOR
570 TICK-BORNE DISEASES IN THE AMERICAS. In: Forum on Microbial Threats;
571 Board on Global Health; Health and Medicine Division; National Academies of
572 Sciences, Engineering, and Medicine. Global Health Impacts of Vector-Borne
573 Diseases: Workshop Summary. Washington (DC): National Academies Press (US).
- 574 52. Centers for Disease Control and Prevention. (2022, March 24). *Diseases Transmitted
575 by Ticks*. Centers for Disease Control and Prevention. Retrieved August 31, 2023.
- 576 53. Brown Marusiak, A., Hollingsworth, B. D., Abernathy, H., Alejo, A., Aahirwa, V.,
577 Mansour, O., Giandomenico, D., Schmitz, J., Williams, C., Barbarin, A. M., & Boyce,
578 R. M. (2022). Patterns Testing for Tick-Borne Diseases and Implications for
579 Surveillance in the Southeastern US. *JAMA network open*, 5(5), e2212334.
- 580 54. Institute of Medicine (US) Committee on Lyme Disease and Other Tick-Borne
581 Diseases: The State of the Science. (2011). Diagnostics and Diagnosis. In *Critical
582 Needs and Gaps in Understanding Prevention, Amelioration, and Resolution of Lyme
583 and Other Tick-Borne Diseases: The Short-Term and Long-Term Outcomes:
584 Workshop Report*. National Academies Press (US).
- 585 55. Elnifro, E. M., Ashshi, A. M., Cooper, R. J., & Klapper, P. E. (2000). Multiplex PCR:
586 optimization and application in diagnostic virology. *Clin Microbiol Rev*, 13(4), 559-
587 70.
- 588 56. Liu, H. Y., Hopping, G. C., Vaidyanathan, U., Ronquillo, Y. C., Hoopes, P. C., &
589 Moshirfar, M. (2019). Polymerase chain reaction and its application in the diagnosis
590 of infectious keratitis. *Medical Hypothesis, Discovery and Innovation in
591 Ophthalmology*, 8(3), 152.
- 592 57. Leeflang, M. M., Ang, C. W., Berkhout, J., Bijlmer, H. A., Van Bortel, W.,
593 Brandenburg, A. H., Van Burgel, N. D., Van Dam, A. P., Dessau, R. B., Fingerle, V.,
594 Hovius, J. W., Jaulhac, B., Meijer, B., Van Pelt, W., Schellekens, J. F., Spijker, R.,
595 Stelma, F. F., Stanek, G., Verduyn-Lunel, F., Zeller, H., ... Sprong, H. (2016). The
596 diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic
597 review and meta-analysis. *BMC infectious diseases*, 16, 140.

- 598 58. Hilton, E., DeVoti, J., Benach, J. L., Halluska, M. L., White, D. J., Paxton, H., &
599 Dumler, J. S. (1999). Seroprevalence and seroconversion for tick-borne diseases in a
600 high-risk population in the northeast United States. *Am J Med*, *106*(4), 404-9.
601 59. Centers for Disease Control and Prevention (CDC). (1995). Recommendations for test
602 performance and interpretation from the Second National Conference on Serologic
603 Diagnosis of Lyme Disease. *MMWR Morb Mortal Wkly Rep*, *44*(31), 590-1.
604 60. Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I., & Wormser, G. P. (2005).
605 Diagnosis of lyme borreliosis. *Clin Microbiol Rev*, *18*(3), 484-509.
606 61. Theel, E. S., Aguero-Rosenfeld, M. E., Pritt, B., Adem, P. V., & Wormser, G. P.
607 (2019). Limitations and Confusing Aspects of Diagnostic Testing for Neurologic
608 Lyme Disease in the United States. *J Clin Microbiol*, *57*(1), e01406-18.
609

610 **Table 1 Sample Cohort**

| Pathogen | N | Source (scientist/company) | Basis of Diagnosis |
|----------------------------------|----------|--|---------------------------|
| <i>Borrelia burgdorferi</i> | 298 | CDC, Private Clinics | RT-PCR, Physician |
| <i>Babesia microti</i> | 70 | Parasitology Laboratory, Wadsworth Center (NYSDOH) | RT-PCR, Blood Smear |
| <i>Babesia microti</i> | 118 | Seracare, Boca Bio, Private Clinics | Serology, RT-PCR |
| <i>Babesia microti</i> | 26 | Renata Welc-Fałęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University) | Physician |
| <i>Bartonella henselae</i> | 119 | Private clinics | RT-PCR, Physician |
| <i>Bartonella henselae</i> | 26 | Renata Welc-Fałęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University) | Physician |
| <i>Bartonella henselae</i> | 10 | Dimosthenis Chochlakis (University of Crete) | Physician |
| <i>Anaplasma phagocytophilum</i> | 118 | Private clinics, Boca Bio | RT-PCR, Serology |
| <i>Anaplasma phagocytophilum</i> | 26 | Renata Welc-Fałęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University) | Physician |
| <i>Ehrlichia chaffeensis</i> | 120 | Private clinics, Boca Bio | RT-PCR, Serology |
| <i>Ehrlichia chaffeensis</i> | 26 | Renata Welc-Fałęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University) | Physician |
| <i>Rickettsia typhi</i> | 70 | Lucas Blanton (University of Texas Medical Branch) | Physician |
| <i>Rickettsia typhi</i> | 124 | Private clinics | RT-PCR, Physician |
| Powassan virus | 127 | Private clinics | RT-PCR, Physician |
| Tick-borne encephalitis | 111 | Daniel Ružek (Czech Academy of Sciences) | Physician |

| | | | |
|--------------------------------|-----|---|-------------------|
| Tick-borne encephalitis | 124 | Private clinics | RT-PCR, Physician |
| West Nile virus | 20 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| West Nile virus | 124 | Private clinics | RT-PCR, Physician |
| Coxsackie virus | 45 | iSpecimen | Serology |
| Coxsackie virus | 124 | Private clinics | RT-PCR, Physician |
| Cytomegalovirus | 43 | DLS | Serology |
| Cytomegalovirus | 138 | Daniele Lilleri (Fondazione IRCCS Policlinico San Matteo) | Physician |
| Cytomegalovirus | 96 | Private Clinics | RT-PCR, Physician |
| Cytomegalovirus | 37 | Seracare | Serology |
| Epstein Barr virus | 20 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| Epstein Barr virus | 43 | Seracare | Serology |
| Epstein Barr virus | 14 | iSpecimen | Serology |
| Epstein Barr virus | 96 | Private clinics | RT-PCR, Physician |
| Parvovirus B19 | 124 | Private clinics | RT-PCR, Physician |
| Toxoplasma gondii | 24 | Seracare | Serology |
| Toxoplasma gondii | 124 | Private clinics | RT-PCR, Physician |
| HSV-1 | 20 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| HSV-1 | 31 | Seracare | Serology |
| HSV-1 | 96 | Private clinics | RT-PCR, Physician |
| HSV-2 | 19 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| HSV-2 | 27 | Seracare | Serology |
| HSV-2 | 96 | Private clinics | RT-PCR, Physician |
| HHV-6 | 20 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| HHV-6 | 96 | Private clinics | RT-PCR, Physician |

611 Table 1 provides an overview of the pathogens used in the study along with the total number
 612 of samples, basis of diagnosis, and sample source.

613

614 **Table 2 Overview of pathogens and antigens**

| <i>Pathogen(Tick, if any)</i> | <i>Antigen</i> |
|---------------------------------------|--|
| <i>B. burgdorferi (I. scapularis)</i> | VlsE1, C6 peptide, DbpB, OspC, p28, p30, OspA, OspB, BmpA, p41, p45, p58, p66, p83-93, WCS B31, WCS 297. |

| | |
|--|--------------------------------|
| <i>B. mayonii</i> (<i>I. scapularis</i>) | Whole cell sonicate |
| <i>B. afzelii</i> (<i>I. ricinus</i> , <i>I. persulatus</i>) | BmpA,DbpA,OspA,OspC,p100 |
| <i>B. garinii</i> (<i>I. ricinus</i> , <i>I. persulatus</i>) | DBpA,OspC |
| <i>B. bavariensis</i> (<i>I. uriae</i> , <i>I. persulcatus</i>) | p58,VLE1, DbpA |
| <i>B. spielmanii</i> (<i>I. ricinus</i>) | DBpA,OspC |
| <i>B. hermsii</i> (<i>O. hermsi</i>) | Whole cell sonicate |
| <i>B. turicatae</i> (<i>O. turicatae</i>) | Whole cell sonicate |
| <i>B. miyamotoi</i> (<i>I. dentatus</i> , <i>I. ricinus</i> , <i>I. scapularis</i> , <i>I. pacificus</i>) | GlpQ |
| <i>B. andersonii</i> (<i>I. dentatus</i>) | Whole cell sonicate |
| <i>B. maritima</i> (<i>I. spinipalpis</i>) | Whole cell sonicate |
| <i>B. californiensis</i> (<i>I. jellisonii</i> , <i>I. spinipalpis</i> , <i>I. pacificus</i>) | Whole cell sonicate |
| <i>B. bissettiae</i> (<i>I. scapularis</i> , <i>I. persulatus</i> , <i>I. spinipalpis</i> , <i>I. pacificus</i>) | Whole cell sonicate |
| <i>B. lusitaniae</i> (<i>I. Ricinus</i>) | Whole cell sonicate |
| <i>B. valaisiana</i> (<i>I. ricinus</i> , <i>I. nipponensis</i> , <i>I. columnae</i>) | Whole cell sonicate |
| <i>B. yangtzensis</i> (<i>I. granulatus</i> , <i>I. nipponensis</i>) | Whole cell sonicate |
| <i>B. turcica</i> (<i>H. aegypticum</i>) | Whole cell sonicate |
| <i>Babesia microti</i> (<i>I. ricinus</i> , <i>I. scapularis</i> , blood transfusions, perinatal) | IRA, p32, p41, WCS |
| <i>Babesia duncani</i> (<i>I. ricinus</i> , <i>I. scapularis</i> , blood transfusions, perinatal) | Whole cell sonicate |
| <i>Bartonella henselae</i> | 17kDa, 26kDa, SucB |
| <i>Bartonella elizabethae</i> | Whole cell sonicate |
| <i>Bartonella vinsonii</i> | Whole cell sonicate |
| <i>Bartonella quintana</i> | Whole cell sonicate |
| <i>Anaplasma phagocytophilum</i> (<i>I. scapularis</i> , <i>I. ricinus</i>) | MSP5, MSP2, OmpA |
| <i>Ehrlichia chaffeensis</i> (<i>Amblyomma americanum</i>) | Whole cell sonicate |
| <i>Rickettsia typhi</i> (<i>Flea Xenopsylla cheopis</i> , <i>Ctenocephalides felis</i>) | Omp B, surface antigen |
| Powassan virus (<i>Hemaphysalis longicornis</i> , <i>I. scapularis</i> , <i>I. cookei</i>) | Whole cell sonicate |
| Tick-borne encephalitis virus (<i>I. ricinus</i> , <i>I. persulcatus</i>) | Whole cell sonicate |
| West Nile virus (<i>I. ricinus</i> , <i>O. moubata</i>) | Whole cell sonicate |
| Coxsackie virus (<i>Amblyomma americanum</i>) | Whole cell sonicate |
| Cytomegalovirus | EIA, gB,p150,p28,p52,pp65,p38 |
| Epstein Barr virus | EA, EBNA1, VCA gp125,p18, p23 |
| Parvovirus B19 | VLP VLP2,VLP VP1/VP2 Co Capsid |
| <i>Toxoplasma gondii</i> (Multiple Ticks) | WCS, MIC3,p24,p29,p30 |

| | |
|-------|---------------------|
| HSV-1 | Whole cell sonicate |
| HSV-2 | Whole cell sonicate |
| HHV-6 | Whole cell sonicate |

615 Table 2 consists of all the pathogens and their respective antigens.

616 **Table 3 Antigen sensitivities**

617

| Pathogen | IgM | | IgG | | IgM+IgG | | Gold Std [34-48] | |
|----------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|------------------------------------|-------------|
| | Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity |
| | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| <i>Borrelia burgdorferi</i> | 60 | 100 | 94 | 100 | 100 | 100 | Early: 30-40 Late: 70-100 | 95-100 |
| <i>Babesia microti</i> | 79 | 98 | 91 | 97 | 99 | 96 | 70-80 | 94-100 |
| <i>Bartonella henselae</i> | 81 | 99 | 96 | 99 | 100 | 98 | 100 | 96.8 |
| <i>Anaplasma phagocytophilum</i> | 94 | 100 | 100 | 100 | 100 | 100 | 80-100 | 95-100 |
| <i>Ehrlichia chaffeensis</i> | 84 | 100 | 100 | 99 | 100 | 99 | 83 | 100 |
| <i>Rickettsia typhi</i> | 86 | 100 | 83 | 100 | 97 | 100 | 80-100 | 91-100 |
| Powassan virus | 100 | 100 | 100 | 100 | 100 | 100 | 89 | 35-84 |
| Tickborne encephalitis | 78 | 99 | 92 | 99 | 93 | 98 | 94-100 | >95 |
| West Nile virus | 25 | 100 | 80 | 100 | 85 | 100 | 80-95 | 94-100 |
| Coxsackie virus | 56 | 100 | 100 | 100 | 100 | 100 | 94-97 | 100 |
| Cytomegalovirus | 100 | 100 | 100 | 100 | 100 | 100 | 89.2 | 95 |
| Epstein Barr virus VCA | 100 | 100 | 96 | 100 | 97 | 100 | 80-95 | >95 |
| Epstein Barr virus EBNA1 | 95 | 100 | 96 | 100 | 97 | 100 | 80-95 | >95 |

| | | | | | | | | |
|---------------------------------|-----|-----|-----|-----|-----|-----|--------|-----|
| Parvovirus B19 | 90 | 99 | 98 | 98 | 99 | 97 | >90 | >90 |
| <i>Toxoplasma gondii</i> | 100 | 99 | 100 | 100 | 100 | 99 | >90 | >95 |
| HSV-1 | 100 | 100 | 98 | 100 | 98 | 100 | 97-100 | 98 |
| HSV-2 | 100 | 100 | 98 | 100 | 98 | 100 | 97-100 | 98 |
| HHV-6 | 95 | 100 | 95 | 100 | 95 | 100 | >95 | >95 |

618 Table 3 shows the IgG, IgM, and IgG+IgM sensitivities and specificities obtained using the
 619 Vibrant microarray and a comparison with the sensitivities and specificities of the current
 620 gold standard for respective pathogens.

621

622 **Table 4 Individual antigen sensitivities (*B. burgdorferi*)**

| Antigen | IgM | IgG |
|---------------------|-----|-----|
| <i>VlsE1</i> | 61% | 91% |
| <i>C6</i> | 39% | 60% |
| <i>B31</i> | 37% | 48% |
| <i>B297</i> | 36% | 57% |
| <i>p18</i> | 6% | 41% |
| <i>p23</i> | 47% | 68% |
| <i>p28</i> | 4% | 28% |
| <i>p30</i> | 5% | 35% |
| <i>p31</i> | 17% | 38% |
| <i>p34</i> | 16% | 41% |
| <i>p39</i> | 29% | 66% |
| <i>p41</i> | 34% | 53% |
| <i>p45</i> | 5% | 35% |
| <i>p58</i> | 5% | 35% |
| <i>p66</i> | 7% | 39% |
| <i>p93</i> | 32% | 60% |

623

624 Table 4 shows the IgG and IgM values for the individual antigens of *Borrelia burgdorferi*




Figure 1: Wafer Processing, Antigen Immobilisation, Pillar Plate Assembly. A poly (lactic acid) and poly (L-lysine) copolymer solution is coated onto the silicon wafers and further immobilized with protein probes [steps 1-3]. The wafers are then diced into microchips using a stealth dicing process [step 4]. A standard die sorting system is used to pick and place the microchips onto carrier plates [step 5]. The carrier tapes are loaded onto a high throughput surface mount technology (SMT) component placement system and individual microchips are placed onto 24-pillar plates. Each pillar consists of 87 microchips [step 6].




Figure 2: Overview of all the pathogens and their respective antigens used in the study.




Figure 3: Heat map showing Lyme disease antigen reactivity. The positivity cutoff for each antigen was set at greater than 10 chemiluminescent units (CU) (shown as yellow or red). The color key is as follows: Red - High positive (CU>20); Yellow, orange - Moderate positive (CU = 10.1-20); White - Negative (CU≤10).